SAN DIEGO, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company
will present a poster on its antifungal VL-2397 development program at the Infectious Diseases Society of America (IDSA) IDWeek
2017, being held in San Diego, CA, from October 4 to 8, 2017. The poster session will be on Friday October 6th from
12:30 to 2:00 pm.
The title of the presentation is “Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397
Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis”. The analysis concluded that a 600 milligram dose of
VL-2397 administered once daily will provide adequate target attainment. The analysis will serve as the basis for using this dosing
regimen in Vical’s upcoming Phase 2 trial in patients with invasive aspergillosis.
Vical also announced today that the company will provide an update on VL-2397 at the 8th Trends in
Medical Mycology (TIMM) Conference, being held in Belgrade, Serbia, from October 6 to 9, 2017. The presentation will be on October
8th at 2:15 pm CET.
Vical plans to conduct a Phase 2 efficacy study to evaluate VL-2397 for the treatment of invasive aspergillosis
and is working with clinical experts and the FDA towards this objective. The FDA has granted Vical Qualified Infectious Disease
Product (QIDP), Orphan Drug and Fast Track designations to VL-2397 for the treatment of invasive aspergillosis. Under the QIDP
designation Vical has been interacting with the FDA on the design of the Phase 2 trial and in exploring an expedited development
pathway for VL‑2397.
About VL-2397
VL-2397 is Vical’s novel antifungal compound that was licensed from Astellas Pharma in 2015. VL-2397 was isolated from
a leaf litter fungus collected in a Malaysian national park and represents the first agent in a potentially new class of antifungal
drugs.
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases,
based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at
www.vical.com.
Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ
materially from those projected. Forward-looking statements include anticipated developments in clinical programs, including the
plans, timing of initiation, and enrollment for clinical trials. Risks and uncertainties include whether Vical or others will
continue development of VL-2397; whether Vical will be able to obtain regulatory allowances or guidance necessary to proceed with
proposed clinical trials or implement anticipated clinical trial designs; whether on-going or planned clinical trials will be
initiated or completed on the timelines Vical currently expects, whether any product candidates will be shown to be safe and
efficacious in clinical trials; whether Vical will have access to sufficient capital to fund its planned development activities;
whether Vical will seek or gain approval to market any product candidates; and additional risks set forth in the Company's filings
with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of
this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
Contact:
Andrew Hopkins
(858) 646-1127
Website: www.vical.com
